GALT vs REG · $142.4M cap vs P/E 34, rev $1.45B
Galectin Therapeutics Inc (GALT) versus Regency Centers Corporation (REG) — a side-by-side from cached financials, not a winner call.
Galectin Therapeutics Inc (GALT) is a biotechnology company listed on US.
Regency Centers Corporation (REG) is a reit - retail company listed on US.
GALT does not have a complete income-statement cache yet.
Latest reported REG revenue for 2024-12-31 was $1.45B. Net income was $409.8M. Revenue was up 9.9% from 2023-12-31 to 2024-12-31. REG currently screens at market cap $12.93B and trailing P/E 33.5.
GALT currently screens at market cap $142.4M. REG currently screens at market cap $12.93B and trailing P/E 33.5.
Not investment advice. Open the GALT and REG stock pages for the full models.
Not investment advice.